Working Group 3 (PCWG3)-modified RECIST v1.1 by blinded independent central review (BICR) Q9W during the first year and then Q12W thereafter. The dual primary end points are radiographic PFS per PCWG3-modified RECIST v1.1, as assessed by BICR and OS. The key secondary end point is time to initiation of subsequent anticancer therapy or death. Other secondary end points include ORR, duration of response, time to PSA progression, time to first symptomatic skeletal-related event, and safety and tolerability. Patient-reported outcomes and identification of molecular biomarkers for treatment response are exploratory end points. KEYLYNK-010 is ongoing or planned in 19 countries across Asia, Australia, Europe, and North and South America.

Results N/A

Conclusions N/A

Trial Registration ClinicalTrials.gov: NCT03834519

Ethics Approval The study and the protocol were approved by the Institutional Review Board or ethics committee at each site.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0345

KEYNOTE-991: PHASE 3 STUDY OF PEMBROLIZUMAB PLUS ENZALUTAMIDE AND ANDROGEN DEPRIVATION THERAPY (ADT) FOR PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER (MHSPC)

1 Christian Gratze, 2 Christian Gratze, 3 Christian Gratze, 4 Csuzen Niu, 5 Christian Poehlein, 6 Joseph Burgents.

University Medical Center Freiburg, Freiburg, Germany; 7MSD China, Beijing, China; 8 Merck and Co., Inc., Rahway, NJ, USA

Background Combination of pembrolizumab, an anti–PD-1 antibody, added to enzalutamide, a nonsteroidal antiandrogen agent, has shown antitumor activity in abiraterone-resistant mCRPC (KEYNOTE-365, NCT02861573) and in patients with mCRPC for whom enzalutamide was ineffective (KEYNOTE-199, NCT02787005). These data indicate that the combination of pembrolizumab + enzalutamide with ADT warrants phase 3 evaluation. Also, efficacy in enzalutamide may be proimmunogenic, suggesting that it may be additive or synergistic in antitumor activity when combined with pembrolizumab.

Methods The KEYNOTE-991 (NCT04191096) phase 3 trial will evaluate the efficacy and safety of enzalutamide + ADT (LHRH agonist/antagonist during study treatment or bilateral orchiectomy) + pembrolizumab or placebo in patients with mHSPC. Eligibility criteria include age ≥ 18 years, mHSPC, ≥ 2 bone lesions or visceral disease, no prior treatment with next-generation hormone agents, adequate organ function, and ECOG PS 0 or 1. Patients must provide tissue for biomarker analysis. Approximately 1232 patients will be randomized in a 1:1 ratio to receive enzalutamide 160 mg orally once daily + ADT + pembrolizumab 200 mg IV every 3 weeks (Q3W) or enzalutamide 160 mg orally once daily + ADT + placebo IV Q3W. Treatment will continue with pembrolizumab up to 35 cycles and treatment with enzalutamide will proceed continuously from day 1 of cycle 1 until disease progression, unacceptable toxicity, or withdrawal of consent. The stratification factors are prior docetaxel therapy (yes or no) and presence of high-volume disease (yes or no). CT or MRI and radionuclide bone imaging will be used to assess response according to Prostate Cancer Working Group 3 (PCWG3)-modified RECIST v1.1 by blinded independent central review (BICR) Q12W from the date of randomization. Imaging will continue until the end of treatment and will resume Q12W during the posttreatment period. The co-primary end points are BICR-assessed radiographic PFS (according to PCWG3-modified RECIST v1.1) and OS. Key secondary end points are time to first subsequent anticancer therapy and time to symptomatic skeletal-related event. Other end points are PFS2 (progression after next line of therapy or death), PSA response rate, time to PSA progression, PSA undetectable rate, ORR, duration of response, time to soft tissue and radiographic bone progression per PCWG3-modified RECIST v1.1, safety, and patient-reported outcomes (eg, time to pain progression). Safety and tolerability will be evaluated using a tiered approach. KEYNOTE-991 is enrolling at 40 sites in Australia, Chile, Colombia, Israel, Japan, Poland, South Korea, Spain, Switzerland, Taiwan, and the United States.

Results N/A

Conclusions N/A

Trial Registration ClinicalTrials.gov: NCT04191096

Ethics Approval The study and the protocol were approved by the Institutional Review Board or ethics committee at each site.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0346

CLINICAL OUTCOMES OF OVARIAN CANCER PATIENTS TREATED WITH ALKS 4230, A NOVEL ENGINEERED CYTOKINE, IN COMBINATION WITH PEMBROLIZUMAB: ARTISTRY-1 TRIAL

1 Ira Winer*, 2 Lucy Gilbert, 3 Ulika Vaidhampayan, 4 Seth Rosen, 5 Christopher Hoimes, 6 Janelle Muzaffar, 7 Anna Spreafico, 8 Deborah Du, 9 Kelly Curtis, 10 Yen Wang, 11 Elizabeth Dorn, 12 Jessica Rege, 13 Yangshun Du, 14 Ilda Bidillar, 15 Lei Sun, 16 Emily Putri, 17 Heather Loney, 18 Bruce Desube, 19 Marc Ermisoff, 20 Vamsidhar Velcheti, 21 James Strauss, 22 Barbara Ann Karnosos Cancer Institute, Wayne State University, Detroit, MI, USA; 23 McGill University Health Centre-Ri, Montreal, Canada; 24 Barbara Ann Karnosos Cancer Institute, Detroit, MI, USA; 25 Hematology Oncology Association of the Treasure Coast, Port St. Lucie, FL, USA; 26 UH Cleveland Medical Center, Cleveland, OH, USA; 27 Moffitt Cancer Center, Tampa, FL, USA; 28 Princess Margaret Cancer Centre, Toronto, ON, Canada; 29 Beth Israel Deaconess Medical Center, Boston, MA, USA; 30 Cross Cancer Institute, University of Alberta/Alberta Health Services, Edmonton, AB, Canada; 31 CHU de Que?bec-Université Laval, Quebec City, Canada; 32 UK Markey Cancer Center, Lexington, KY, USA; 33 Summit Cancer Centers, Spokane, WA, USA; 34 Klinika Onkologii Oddzial Chemioterapii, Poznan, Poland; 35 START Madrid Centro Oncologico Clara Campal (CIOCC), Madrid, Spain; 36 CIDC, Madrid, Spain; 37 Case Western Reserve University, Thoracic Oncology Program, Case Comprehensive Cancer Center University Hospitals, Seidman Cancer Center Cleveland, Cleveland, OH, USA; 38 Genomics Health, Raleigh, NC, USA; 39 Alkermes, Inc., Waltham, MA, USA; 40 Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA; 41 Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA; 42 Mary Crowley Cancer Research, Dallas, TX, USA

Background ALKS 4230 is a novel engineered cytokine that selectively targets the intermediate-affinity interleukin-2 receptor complex to activate CD8+ T cells and natural killer cells. The ARTISTRY-1 trial (NCT02799095) has shown encouraging efficacy and acceptable tolerability of ALKS 4230 among patients with advanced solid tumors. We report a detailed analysis of ovarian cancer (OC) patients who received combination therapy in ARTISTRY-1.

Methods ARTISTRY-1 is an ongoing multicohort phase 1/2 trial exploring intravenous ALKS 4230 as monotherapy and combined with pembrolizumab. OC patients were enrolled into a cohort with mixed anti PD 1/L1 unapproved tumor types who had progressed on prior chemotherapy. OC patients received ALKS 4230 (3 μg/kg) on days 1–5 and pembrolizumab (200 mg) on day 1 of a 21 day cycle. Outcomes
Abstract

Table 1 Summary of response observations among patients with ovarian cancer

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>Prior Therapies</th>
<th>Max. Reduction of Target Lesions (%)</th>
<th>OR*</th>
<th>CA125 (U/mL) Response From Baseline</th>
<th>Time on ALKS 4230 (Weeks)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>48</td>
<td>CBB/PAC/HEV, CBB/PAC/PHEV, CBB/PAC/FLD, PBA/FCI, PBA/CBB/FLD</td>
<td>70.6</td>
<td>CBB</td>
<td>Normalized from 262 to 34.5 at cycle 4</td>
<td>81 vi</td>
</tr>
<tr>
<td>2</td>
<td>83</td>
<td>CBB/PAC/DOD, CBB/PAC/DOD/QTAM, CBB/PAC/DDC</td>
<td>76.3</td>
<td>PR</td>
<td>Normalized from 125 to 16 at cycle 8</td>
<td>23 vi</td>
</tr>
<tr>
<td>3</td>
<td>60</td>
<td>CBB/PAC, CBB/PAC/DOD, CBB/PAC/DDC, PBA/FCI</td>
<td>44.7</td>
<td>uPR</td>
<td>Normalized from 106 to 5 at cycle 4</td>
<td>34</td>
</tr>
<tr>
<td>4</td>
<td>75</td>
<td>CBB/PAC, CBB/PAC/DDC, CBB/PAC/DOD, PBA/FCI</td>
<td>21.8</td>
<td>SD</td>
<td>Normalized from 163 to 5 at cycle 8</td>
<td>14 vi</td>
</tr>
<tr>
<td>5</td>
<td>83</td>
<td>CBB/PAC, CBB/PAC/HEV, CBB/PAC/DDC, PBA/FCI</td>
<td>18.3</td>
<td>SD</td>
<td>Normalized from 106 to 15 at cycle 4</td>
<td>21 vi</td>
</tr>
</tbody>
</table>

*As assessed by the investigator.

Table 347 Table 1 Summary of response observations among patients with ovarian cancer

Abstract 347 Figure 1 Increased markers of lymphocyte tumor infiltration
An increase in CD3+CD8+ T cells (A, red = CD3; blue = CD8; purple = CD3+CD8+; teal = tumor marker), GranzymeB (B, red = CD8; green = granzymeB; yellow = granzymeB+CD8+; teal = tumor marker), and PD-L1 (C, red = PD-L1; blue = PD-L1; tumor marker) in the tumor microenvironment of a single patient was observed after the patient received monotherapy ALKS 4230.

have generally been transient and manageable, with the majority being grade 1 and 2 in severity. Overall, based on preliminary data, the combination with ALKS 4230 did not demonstrate any additive toxicity to that already established with pembrolizumab alone. Additional safety and efficacy data are being collected in ongoing cohorts. In the monotherapy dose escalation portion of the study, ALKS 4230 alone increased markers of lymphocyte infiltration in 1 paired melanoma biopsy (1 of 1; on treatment at cycle 2); CD8+ T cell density and PD-L1 tumor proportion score increased 5.2- and 11 fold, respectively, supporting evidence that ALKS 4230 has immunostimulatory impact on the TME and providing rationale for combining ALKS 4230 with pembrolizumab (figure 1).

Conclusions The combination of ALKS 4230, an investigational agent, and pembrolizumab demonstrates an acceptable safety profile and provides some evidence of tumor shrinkage and disease stabilization in some patients with heavily pretreated OC. This regimen could represent a new therapeutic option for these patients.

Acknowledgements The authors would like to thank all of the patients who are participating in this trial and their families. The trial is sponsored by Alkermes, Inc. Medical writing and editorial support was provided by Parexel and funded by Alkermes, Inc.

Trial Registration ClinicalTrials. gov NCT02799095

Ethics Approval This trial was approved by Ethics and Institutional Review Boards (IRBs) at all trial sites; IRB reference numbers 16–229 (Dana-Farber Cancer Institute), MOD00003422/PH285316 (Roswell Park Comprehensive Cancer Center), 20160175 (Western IRB), i15-01394_MOD23 (New York University School of Medicine), TRIAL20190090 (Cleveland Clinic), and 000097 (ADVARRA).

REFERENCES
2. Vaidyanapayun UN, Muzaffar J, Velcheti V, Winer I, Hoimes CJ, Rosen SD, et al. ALKS 4230 monotherapy and in combination with pembrolizumab (pembro) in patients (pts) with refractory solid tumors (ARTISTRY-1). Oral presentation at: European Society for Medical Oncology Annual Meeting; September 2020; virtual.

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0347

348 A PHASE 2 UMBRELLA STUDY OF RETIFANLIMUB (INCMGA00012) ALONE OR IN COMBINATION WITH OTHER THERAPIES IN PATIENTS WITH ADVANCED OR METASTATIC ENDOMETRIAL CANCER (PUD1UM-204, GOG 3038, ENGOT-EN12/NOGGO)

Brian Somrovitz*, Bradley Monk, Katherine Moxley, Nadeem Ghalii, Justyna Fraczek Sokol, Chuan Tian, Nawel Bourayou, Jalid Sehouli. Florida International University, Fort Lauderdale, FL, USA; Saint Joseph’s Hospital and Medical Center, Phoenix, AZ, USA; University of Oklahoma Health Sciences, Oklahoma City, OK, USA; Incyte Corporation, Wilmington, DE, USA; Incyte Biosciences International Sarl, Morges, Switzerland; Medical University of Berlin, Berlin, Germany

Background Management of advanced endometrial cancer after failure with platinum therapy remains a challenge. Tumors characterized by DNA repair abnormalities are associated with high numbers of neoantigens; immunotherapy is promising in this setting as demonstrated in studies with checkpoint inhibitors (CPI). 1-6 Overcoming emerging resistance to CPI through novel combinations is a focus of research. Retifanlimub is an investigational humanized immunoglobulin G4 monoclonal

http://dx.doi.org/10.1136/jitc-2020-SITC2020.0347